Market closedADR

Barinthus Biotherapeutics/$BRNS

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Barinthus Biotherapeutics

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.

Ticker

$BRNS
Trading on

Industry

Biotechnology

Employees

130

BRNS Metrics

BasicAdvanced
$56M
Market cap
-
P/E ratio
-$1.49
EPS
-0.58
Beta
-
Dividend rate
$56M
-0.58
$4.16
$1.11
42K
8.934
8.435
6.699
7.945
-1,301.04%
-18.65%
-32.60%
3.642
0.35
0.45
-0.878
106.21%
-26.59%
188.56%
-15.13%

What the Analysts think about BRNS

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Barinthus Biotherapeutics stock.

BRNS Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BRNS Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BRNS

$

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Barinthus Biotherapeutics stock?

Barinthus Biotherapeutics (BRNS) has a market cap of $56M as of November 14, 2024.

What is the P/E ratio for Barinthus Biotherapeutics stock?

The price to earnings (P/E) ratio for Barinthus Biotherapeutics (BRNS) stock is 0 as of November 14, 2024.

Does Barinthus Biotherapeutics stock pay dividends?

No, Barinthus Biotherapeutics (BRNS) stock does not pay dividends to its shareholders as of November 14, 2024.

When is the next Barinthus Biotherapeutics dividend payment date?

Barinthus Biotherapeutics (BRNS) stock does not pay dividends to its shareholders.

What is the beta indicator for Barinthus Biotherapeutics?

Barinthus Biotherapeutics (BRNS) has a beta rating of -0.58. This means that it has an inverse relation to market volatility.